|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US7687075||SALIX PHARMS||Colonic purgative composition with soluble binding agent|| |
(4 years from now)
Osmoprep is owned by Salix Pharms.
Osmoprep contains Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Monobasic, Monohydrate.
Osmoprep has a total of 1 drug patent out of which 0 drug patents have expired.
Osmoprep was authorised for market use on 16 March, 2006.
Osmoprep is available in tablet;oral dosage forms.
The generics of Osmoprep are possible to be released after 22 June, 2028.
Market Authorisation Date: 16 March, 2006
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic